Nailfold Capillary Blood Flow With Latanoprost Bunod

Status Completed

Clinical Trial Summary

The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the movement of blood in small blood vessels. It is simple, safe and does not penetrate the skin. The skin fold that is at the tip of the finger is called the "nailfold". NFC has been used to assess blood vessel narrowing in patients with glaucoma.

Clinical Trial Description

In this study, the study team investigates the effect of topically-applied latanoprostene bunod (LTB) on the blood flow at the nailfold of the 4th finger in patients with primary open angle glaucoma. LTB is a new anti-glaucoma eye drop which received FDA clearance in early November 2017. It has two components: the prostaglandin analog (PGA) which decreases intraocular pressure (IOP) by enhancing the drainage of the aqueous (the fluid in the front part of the eye) from the eye, and the nitric oxide (NO) moiety which naturally dilates arteries in the body. The capillaries at the nailfold are comparable to those of the optic nerve head, which makes them a reasonable surrogate for evaluation of the effect of LTB on the blood flow. Therefore, this study may provide indirect evidence for the beneficial effect of LTB on blood flow to optic nerve which can potentially save the optic nerve from glaucomatous damage. Primary open angle glaucoma is a progressive condition and is the most common cause of irreversible blindness worldwide. Primary open angle glaucoma (POAG) is a subset of the glaucomas defined by an open, normal appearing anterior chamber angle and raised intraocular pressure (IOP), with no other underlying disease. In addition to LTB, the study team will use latanoprost (L), an-FDA approved PGA anti-glaucoma eye drop and normal saline (NS: the physiologic solution composed of 0.9% salt and water), as controls to make sure the effects of LPB on nail fold capillary blood flow is not due to its PGA (as L is) or due to the placebo effect (as NS is). This study may also serve as background information for the development of new anti-glaucoma medications which can be injected into the eye to facilitate blood flow to the optic nerve. ;

Study Design

Related Conditions & MeSH terms

Glaucoma, Open-Angle

Clinical Trial Details

NCT number	NCT03949244
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	Phase 4
Start date	August 15, 2019
Completion date	October 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05044793` - A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System
Recruiting	`NCT06201455` - Evaluation of Phacogoniotomy in Medically-controlled POAG	N/A
Recruiting	`NCT03369886` - The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI	N/A
Active, not recruiting	`NCT04624698` - iStent Inject New Enrollment Post-Approval Study	N/A
Recruiting	`NCT02679482` - Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma	N/A
Completed	`NCT02338362` - Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma	Phase 4
Active, not recruiting	`NCT01430923` - Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost	N/A
Completed	`NCT01489670` - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension	N/A
Completed	`NCT00693485` - Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy	Phase 2
Completed	`NCT00753168` - Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma	Phase 1/Phase 2
Completed	`NCT00051194` - A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension	Phase 2
Recruiting	`NCT04920227` - Comparation of CLASS Combined With Phacoemulsification and CLASS Alone in the Treatment of Primary Open Angle Glaucoma	N/A
Active, not recruiting	`NCT03868124` - Clinical Study Comparing Two Models of a Travoprost Intraocular Implant	Phase 3
Completed	`NCT03267862` - Scleral Response to Intraocular Pressure (IOP)	N/A
Recruiting	`NCT06066645` - Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone	Phase 3
Recruiting	`NCT04912362` - The Effectiveness of YAG Iridotomy in Preventing Peripheral Anterior Synechia After CLASS in Primary Open Angle Glaucoma	N/A
Completed	`NCT04949802` - Glaucoma Surgery Using the ViaLase Laser System	N/A
Recruiting	`NCT04038034` - Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma	N/A
Completed	`NCT04632329` - Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma	N/A
Completed	`NCT01215786` - Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma	Phase 1